## **CERTIFICATE OF OFFICER**

Pursuant to subsection 2.20(c) of National Instrument 54-101 – *Communication with Beneficial Owners of Securities of a Reporting Issuer* (**NI 54-101**), and in connection with the annual general and special meeting of shareholders of Rapid Dose Therapeutics Corp. (the **Company**) to be held on December 6, 2019 (the **Meeting**), the undersigned, Ian Fodie, Chief Financial Officer of the Company, hereby certifies for and on behalf of the Company, and not in his personal capacity and without personal liability, that the Company:

- 1 has arranged to have proxy-related materials for the Meeting sent in compliance with the applicable timing requirements prescribed in sections 2.9 and 2.12 of NI 54-101, as applicable;
- 2 has arranged to have carried out all of the requirements of NI 54-101 in addition to those described in paragraph 1 above; and
- 3 is relying upon section 2.20 of NI 54-101 to abridge the time periods prescribed in subsections 2.2(1) and 2.5(1) of NI 54-101.

DATED this 15<sup>th</sup> day of November 2019.

## RAPID DOSE THERAPEUTICS CORP.

Per: "lan Fodie"

Name: Ian Fodie Title: Chief Financial Officer